Open AccessLong-Term Immunogenicity of Hepatitis A Virus Vaccine in Alaska 17 Years After Initial Childhood Series
Author(s) -
Gregory Raczniak,
Lisa Bulkow,
Michael G. Bruce,
Carolyn Zanis,
Richard L. Baum,
Mary Snowball,
Kathy K. Byrd,
Umid Sharapov,
Thomas W. Hennessy,
Brian J. McMahon
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis710
Subject(s) - immunogenicity , hepatitis a vaccine , medicine , hepatitis a virus , immunization , vaccination , hepatitis a , virology , antibody , immunology , virus , pediatrics , hepatitis
The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom